Generated by AI
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Taysha Gene Therapies works on treatments designed to address the genetic root causes of rare neurological disorders, with a pipeline that includes programs for Rett syndrome, giant axonal neuropathy, CLN1 disease, CLN7 disease, SLC13A5 deficiency, fragile X syndrome, angelman syndrome, and tauopathies. The company’s current work centers on advancing its lead clinical programs and translating AAV gene therapy platforms into potential disease-modifying medicines for underserved patient populations. Based in Dallas, Texas, Taysha Gene Therapies operates within the broader biotechnology sector, where it contributes to the development of specialized therapies for rare central nervous system disorders.
Website3000 Pegasus Park Drive
Dallas, TX, 75247
United States
The latest articles about TSHA.
Summary of Jun 25's posts. Generated by AI.
Summary of Oct 3's posts. Generated by AI.
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Com
Summary of Aug 15's posts. Generated by AI.
Summary of Oct 17's posts. Generated by AI.
Investors talking about TSHA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.